Stago BV

HemoSonics' Quantra® Hemostasis Analyzer provides comprehensive blood analysis that details critical bleeding disorders and helps clinicians manage patients back into hemostasis. The Quantra System has the broadest range of FDA-cleared indications for use in its category and is cleared for use with arterial and venous blood samples in cardiac, trauma, liver, and major orthopedic surgery patients. DURHAM, N.C., April 3, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. Today's announcement enables hospitals to further standardize and operationalize viscoelastic testing with an arterial and venous indication for both HemoSonics' QStat Cartridge and the QPlus® Cartridge. "The FDA 510(k) clearance for arterial blood sample use with our QStat Cartridge will make it easier and more convenient for hospitals to use the Quantra System," said Bob Roda, President and CEO of HemoSonics. "The Quantra System now has the broadest range of FDA-cleared clinical indications of any cartridge-based viscoelastic testing system. It is cleared for use in cardiac, trauma, liver, and major orthopedic surgeries. We will continue to innovate in our mission to help patients and hospitals preserve blood, which is a precious resource." HemoSonics' Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, which enable clinicians to deliver patient-centered decisions on bleeding management that improve care and optimize blood product usage. The Quantra System is FDA-cleared for use in point-of-care settings such as operating rooms, intensive care units, and in hospital laboratories, enabling hospitals to standardize use institution-wide with greater operational efficiency. The Quantra System allows healthcare professionals to make individualized and evidence-based decisions on how to manage a bleeding patient and give a patient only medically appropriate therapy – an approach that supports global initiatives to reduce inappropriate transfusions of blood products. The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory-based settings, typically in less than 15 minutes. The American Red Cross declared a blood shortage emergency in January 2024, and preserving blood is more important for medical care facilities and their communities than ever. Additionally, blood acquisition remains the most significant expense for hospital blood banks. HemoSonics' Quantra technology helps patients and hospitals by preserving precious blood supplies: a 2023 Journal of Cardiothoracic Surgery study showed that implementation of the Quantra Hemostasis Analyzer with the QPlus Cartridge reduced utilization of blood components by up to 90%, allowing greater availability for those patients truly in need. In addition, the cost of blood products decreased by 41%. Email sales@hemosonics.com or visit to learn more. About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit HemoSonics.com to learn more. All trademarks contained herein are the property of their respective owners.

Honored by Fast Company in the medical device category for its easy-to-operate Quantra® Hemostasis System that provides fast, comprehensive whole-blood coagulation analysis at the point of care, HemoSonics joins Abbott, Amgen, Bristol Myers Squib, Novartis, Scopio Labs and others as the recipient of this prestigious award DURHAM, N.C. , March 21, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has been named to the prestigious list of Fast Company's Most Innovative Companies for 2024. The annual Fast Company flagship awards spotlight companies at the forefront of their respective industries and recognize organizations and products that are transforming industries through their innovations, setting new standards, and achieving remarkable milestones that are moving the world forward. HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others. We are honored to be recognized by Fast Company for our groundbreaking Quantra Hemostasis System. "We are honored to be recognized by Fast Company for our groundbreaking Quantra Hemostasis System, which provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes," said HemoSonics CEO and President Bob Roda. "Blood is a precious, critical resource. The Quantra Hemostasis System can minimize the use of generic transfusion regimens in massive hemorrhages that result in some patients being over-treated and others inadequately supported. Our data-driven approach and point-of-care technology enable clinicians to make better and more informed blood transfusion decisions, make transfusions safer and improve patient outcomes, and reduce the waste of blood, which can be preserved for other patients in critical need." HemoSonics' Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus® and QStat® Cartridges, which enable clinicians to deliver patient-centered coagulation therapy that improves care and optimizes blood product usage. HemoSonics' Quantra System has the broadest range of FDA-cleared clinical indications of any viscoelastic testing analyzer. The Quantra System is FDA-cleared for use in point-of-care settings such as operating rooms, intensive care units, and hospital laboratories, enabling hospitals to standardize its use institution-wide. The Quantra System allows for individualized medicine by informing the decision to give a patient only the blood products that they need. The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory-based settings, typically in less than 15 minutes. The World's Most Innovative Companies is Fast Company's hallmark franchise and one of the year's most anticipated awards for groundbreaking innovations. Fast Company's editorial team identified the 2024 Most Innovative Companies driving progress worldwide and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the world's most valuable companies. "Our list of the Most Innovative Companies is both a comprehensive look at the innovation economy and a snapshot of the business trends that defined the year," said Fast Company editor-in-chief Brendan Vaughan. "We saw extraordinary innovation across the board in 2023, but we also saw a handful of clear patterns: the growing footprint and impact of AI, the triumphant return of live events, and great leaps forward in climate tech. We face daunting challenges on many fronts, but the solutions we celebrate in Most Innovative Companies give me plenty of hope about the future." About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit HemoSonics.com to learn more. About Fast Company Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at . View original content to download multimedia: SOURCE HEMOSONICS LLC

HemoSonics wins in product launch and business expansion categories as more hospitals adopt its Quantra® Hemostasis System for acute bleeding management DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics, a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards. HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes. Clinicians don't need to wait on test results during a serious life-threatening bleeding event, and, as a result, patients receive optimized interventions as quickly as possible and only when needed. The Medical Device Network Excellence Awards is an independent recognition program powered by the business intelligence of GlobalData. Researchers and journalists, along with artificial Intelligence, analyze over one billion datasets during the year, then recognize, endorse, and rank top-tier companies and their achievements in 200+ countries. During the evaluation period, HemoSonics secured 510(k) clearance for the QStat® Cartridge from the U.S. Food and Drug Administration (FDA), allowing its Quantra Hemostasis System to be used in laboratory and point-of-care settings for trauma and liver transplantation procedures. HemoSonics also received an innovative technology contract award from Vizient, opening the door for the System to be adopted by hospitals and academic medical centers across the United States. "These awards validate the hard work and dedication of the HemoSonics team and our healthcare partners to advance technology that improves patient care and outcomes," said Bob Roda, President and CEO of HemoSonics. "At the same time, we are just getting started. We will continue to innovate and bring to the healthcare marketplace, new technology solutions to support our clinical partners and hospitals transform patient care, preserve blood, and reduce healthcare resource utilization." The Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus® and QStat Cartridges. Quantra is FDA-cleared for use in point-of-care settings, such as operating rooms, intensive care units, and in hospital laboratories, and requires minimal resources to maintain, operate, and to interpret. HemoSonics' medical device technology is proven to help patients and hospitals: a 2023 Journal of Cardiothoracic Surgery study showed the Quantra Hemostasis System reduced blood component transfusions between 10% and >90%. This led to a 41% decrease in the cost of blood products - a major expense for hospitals. It is also recognized that with improved outcomes supported by reduced exposure to risky blood component therapy, additional cost and efficiency benefits are realized. About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve upon existing strategies for bleeding management, and support better patient outcomes and reduce healthcare costs. The Quantra System's easy and fast interpretation enables simple, more efficient, point-of-care bleeding management. Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to thrombosis and hemostasis. Visit HemoSonics.com to learn more. View original content to download multimedia: SOURCE HEMOSONICS LLC